Pair Name	Quercetin, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP7	hsa840
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Down-regulation	Expression	Trx1	KEGG ID N.A.
	Down-regulation	Expression	Trx2	KEGG ID N.A.
	Down-regulation	Expression	TrxR	KEGG ID N.A.
In Vitro Model	SK-OV-3	Ovarian serous cystadenocarcinoma	Homo sapiens (Human)	CVCL_0532
	SKOV-3/CDDP	Cisplatin-resistant ovarian serous cystadenocarcinoma	Homo sapiens (Human)	N.A.
Result	This study provides further new data for the mechanism by which the QU pre-treatment re-sensitizes SKOV-3/CDDP cells to cisplatin.

Pair Name	Quercetin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP8	hsa841
	Up-regulation	Expression	CASP9	hsa842
In Vitro Model	K-562	Blast phase chronic myelogenous leukemia	Homo sapiens (Human)	CVCL_0004
Result	These findings demonstrated that quercetin is important in MDR and may be developed into a new reversal agent for cancer chemotherapy.

Pair Name	Quercetin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	These findings demonstrated that quercetin is important in MDR and may be developed into a new reversal agent for cancer chemotherapy.

Pair Name	Quercetin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->ROS accumulation
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	MYC	hsa4609
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vivo Model	Into the right hind limb of each nude mouse, 2×10⁶ 4 T1 TNBC cells were injected subcutaneously. One week later, the mice were randomly divided into four groups (n = 3): control group (0.9% saline); Que group (50 mg/kg Que); AC group (5 mg/kg Dox plus 50 mg/kg Cyc); and AC plus Que group (5 mg/kg Dox plus 50 mg/kg Cyc plus 50 mg/kg Que).
Result	Que could attenuate AC-induced cardiotoxicity by inhibiting ROS accumulation and activating ERK1/2 pathway in cardiomyocytes, but interestingly, Que could enhance the antitumor activity of AC by inhibiting ROS accumulation and ERK1/2 pathway in TNBC cells. In addition,in vivo studies further confirmed that Que could enhance the chemotherapeutic effect of AC against TNBC while it reduced the injury of cardiotoxicity induced by AC

Pair Name	Quercetin, Anti-PD-1 antibody
Partner Name	Anti-PD-1 antibody
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Reshaped-->Tumor immune microenvironment
Gene Regulation	Up-regulation	Expression	ARG1	hsa383
	Up-regulation	Expression	CD4	hsa920
	Up-regulation	Expression	CD8A	hsa925
	Up-regulation	Expression	IFNG	hsa3458
	Up-regulation	Expression	IL10	hsa3586
	Down-regulation	Expression	IL12A	hsa3592
	Down-regulation	Expression	IL1B	hsa3553
	Down-regulation	Expression	IL4	hsa3565
	Down-regulation	Expression	IL6	hsa3569
	Up-regulation	Expression	ITGAM	hsa3684
	Up-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	NFKBIA	hsa4792
	Down-regulation	Expression	RELA	hsa5970
	Up-regulation	Expression	TGFB1	hsa7040
	Down-regulation	Expression	TLR4	hsa7099
	Down-regulation	Expression	TNF	hsa7124
In Vivo Model	Orthotopically transplanted HCC tumors in mice were treated with quercetin, anti-PD-1 antibody, or a combination of both therapies.
Result	Quercetin/anti-PD-1 antibody combination therapy reshaped HCC tumor microenvironment in mice in parallel with regulating the GM and macrophage immunity.

Pair Name	Quercetin, Docetaxel
Partner Name	Docetaxel
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Proliferation and apoptosis
In Vitro Model	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
Result	Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells

Pair Name	Quercetin, Oxaliplatin
Partner Name	Oxaliplatin
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	CYCS	hsa54205
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vivo Model	To generate HCT116 xenografts in BALB/c nude mice, 3×10⁶ HCT116 cells were subcutaneously injected into the left and right flanks of each mouse.
Result	These findings suggest that the depletion of intracellular glutathione by quercetin and sulforaphane could strengthen the anti-cancer efficacy of oxaliplatin.

Pair Name	Quercetin, Cyclophosphamide
Partner Name	Cyclophosphamide
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Immunomodulatory
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	4T1 cells (5×10³) in 100 µL of phosphate-buffered saline (PBS) were injected into one axillary mammary fat pad per mouse of 5–6-week-old female immunocompetent BALB/c mice.
Result	Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model

Pair Name	Quercetin, Docetaxel
Partner Name	Docetaxel
Disease Info	[ICD-11: 2E02]	Metastatic prostate cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	AR	hsa367
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	PIK3CA	hsa5290
In Vitro Model	PC-3-R	Prostate carcinoma	Homo sapiens (Human)	CVCL_C0QS
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
In Vivo Model	5×10⁵ PC-3 cells were suspended in 100 μL PBS, or 2×108 LNCaP cells were suspended in 100 μL of matrigel, while PBS mixture (1:1) were injected subcutaneously into the right axillary fossa of mice.
Result	Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways

Pair Name	Quercetin, Fluorouracil
Partner Name	Fluorouracil
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	HMOX1	hsa3162
	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
Result	Our results suggest that Que reverses 5-FU resistance in CC cells via modulating the Nrf2/HO-1 pathway.

Pair Name	Quercetin, Fluorouracil
Partner Name	Fluorouracil
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
In Vitro Model	HT-29	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0320
In Vivo Model	Rats were assigned to two groups. The 5-FU/quercetin group received intraperitoneal quercetin (10 mg/kg) and the Tween was injected to the control group for 14 consecutive days. On the 15th day, both groups received 50 mg/kg of 5-FU.
Result	Interaction of quercetin and 5-fluorouracil: cellular and pharmacokinetic study